雜志介紹

Leukemia & Lymphoma雜志介紹

《Leukemia & Lymphoma》是一本以(yi)English為主(zhu)(zhu)的(de)(de)(de)未開放獲取國(guo)際優秀期刊，中文名稱白血病和淋巴瘤，本刊主(zhu)(zhu)要出版、報道醫學-HEMATOLOGY領域的(de)(de)(de)研究(jiu)動態以(yi)及在該(gai)(gai)(gai)領域取得的(de)(de)(de)各方面的(de)(de)(de)經驗和科研成果，介紹(shao)該(gai)(gai)(gai)領域有關本專(zhuan)業(ye)的(de)(de)(de)最(zui)(zui)新(xin)進(jin)展(zhan)，探(tan)討行(xing)(xing)業(ye)發(fa)展(zhan)的(de)(de)(de)思(si)路和方法，以(yi)促(cu)進(jin)學術(shu)信(xin)息(xi)交流，提(ti)高行(xing)(xing)業(ye)發(fa)展(zhan)。該(gai)(gai)(gai)刊已被國(guo)際權威數據庫SCIE收錄(lu)，為該(gai)(gai)(gai)領域相關學科的(de)(de)(de)發(fa)展(zhan)起到了(le)良好的(de)(de)(de)推動作用，也得到了(le)本專(zhuan)業(ye)人員的(de)(de)(de)廣泛認可。該(gai)(gai)(gai)刊最(zui)(zui)新(xin)影(ying)響因(yin)子為2.2，最(zui)(zui)新(xin)CiteScore 指數為4.1。

本刊近期中國學者發表的論文主要有：

• YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma

  Author: Yin, Qingqing; Shen, Xianjuan; Xu, Honglei; Feng, Wei; Shi, Xiuying; Ju, Shaoqing

• Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma

  Author: Ma, Guangyu; Gao, Yuhuan; Jing, Xiaotong; He, Cuiying; Liu, Haisheng; Wu, Xiaolin; Gao, Zhe; Li, Yuan; Zhang, Shengnan; Zhao, Guimin

• IFN-gamma enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway

  Author: Shao, Xiaoya; Meng, Xueqiong; Yang, Haiping; Wang, Xinxin; Qin, Ling; Shen, Guomin; Xi, Xiaoping; Zhao, Huijuan; Macip, Salvador; Chen, Yixiang

• Circulating mitochondrial DNA is associated with anemia in newly diagnosed hematologic malignancies

  Author: Yue, Liang; Li, Yu-Hang; Ma, Rui-Lin; Niu, Jing-Wen; Cui, Hong-Tu; Sun, Yao; Yun, Zhi-Min; Zhuo, Hai-Long; Wan, Lu-Ming; Li, Su-Bo; Zhang, Xue; Wu, Cheng-Jun; Hu, Liang-Ding; Tan, Ying-Xia

英文介紹

Leukemia & Lymphoma雜志英文介紹

Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor